Back to search
C3 Nephropathy
Clinical trial pipeline · Data from ClinicalTrials.gov
See which C3 Nephropathy trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which C3 Nephropathy trials you may qualify forThis study is the first time the new medicine CPV-104 is being tested in people. CPV-104 is designed to regulate the complement system, which can be overactive…
This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan in subjects with C3 glomerulopathy or idiopathic…
The aim of this cross-over trial is to assess aliskiren, a direct renin inhibitor, as a novel treatment to block complement activation in the kidneys and thereb…
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research. The purpo…
The purpose of AROC3-1001 is to evaluate the safety, tolerability, pharmacokinetics and/or pharmacodynamics in adult healthy volunteers (HVs) and in adult patie…
This is a post-marketing surveillance study conducted as part of the Risk Management Plan (RMP) for South Korea, to evaluate the safety and effectiveness of ipt…
This is a Phase 2, multicenter, open-label, randomized, controlled study designed to evaluate the safety and efficacy of pegcetacoplan in patients who have post…